Therabron Therapeutics Initiates Phase 2 Clinical Study for Orphan Drug CG100
PHASE 2 STUDY SUPPORTED BY A $1.6M GRANT FROM THE FDA OFFICE OF ORPHAN PRODUCT DEVELOPMENT
Therabron Therapeutics, a privately held clinical stage biopharmaceutical company, today announced that it has initiated the Phase […]